Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study.

Abstract

OBJECTIVES:

Hyperprolactinemia is an important but often overlooked adverse effect of antipsychotics. Several studies have shown that switching to or adding aripiprazole normalizes antipsychotic-induced hyperprolactinemia. However, no study has directly compared the effectiveness and safety of the 2 strategies.

METHODS:

A total of 52 patients with antipsychotic-induced hyperprolactinemia were recruited. Aripiprazole was administered to patients with mild hyperprolactinemia (serum prolactin level < 50 ng/mL). Patients with severe hyperprolactinemia (serum prolactin level > 50 ng/mL) were randomized to an aripiprazole-addition group (adding aripiprazole to previous antipsychotics) or a switching group (switching previous antipsychotics to aripiprazole). Serum prolactin level, menstrual disturbances, sexual dysfunction, psychopathologies, and quality of life were measured at weeks 0, 1, 2, 4, 6, and 8.

RESULTS:

Both the addition and switching groups showed significantly reduced serum prolactin level and menstrual disturbances and improved sexual dysfunction. In patients with severe hyperprolactinemia, the numbers of patients with hyperprolactinemia and menstrual disturbance in the switching group were significantly lower than those in the addition group at week 8.

CONCLUSIONS:

Both the addition and switching strategies were effective in resolving antipsychotic-induced hyperprolactinemia and hyperprolactinemia-related adverse events, including menstrual disturbances and sexual dysfunction. In addition, these findings suggest that switching to aripiprazole may be more effective than addition of aripiprazole for normalizing hyperprolactinemia and improving hyperprolactinemia-related adverse events in patients with schizophrenia.

• Authors: Hui Woo Yoon, Jung Suk Lee, Sang Jin Park, Seon-Koo Lee, Won-Jung Choi, Tae Yong Kim, Chang Hyung Hong, Jeong-Ho Seok, Il-Ho Park, Sang Joon Son, Daeyoung Roh, Bo-Ra Kim, Byung Ook Lee
• Journal: Clinical neuropharmacology (Clin Neuropharmacol) 2016 Nov/Dec Vol. 39 Issue 6 Pg. 288-294 ISSN: 1537-162X [Electronic] United States
• PMID: 27438182 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Antipsychotic Agents
• Aripiprazole
• Prolactin

Topics

• Adolescent
• Adult
• Antipsychotic Agents (adverse effects)
• Aripiprazole (therapeutic use)
• Drug Synergism
• Female
• Humans
• Hyperprolactinemia (blood, chemically induced, drug therapy)
• Male
• Menstruation Disturbances (chemically induced, drug therapy)
• Mental Disorders (drug therapy)
• Middle Aged
• Prolactin (blood)
• Prospective Studies
• Severity of Illness Index
• Sexual Dysfunction, Physiological (chemically induced, drug therapy)
• Time Factors
• Young Adult